U of MD lab to double in size; Cannabis raises working capital in EU;

 @FierceBiotech: Roche, Genentech hit with refuse-to-file letter. Article  | Follow @FierceBiotech

> A University of Maryland lab where some of the state's biggest names in biotechnology have developed early-stage drug candidates and other biologics is about to double in size and add staff. News

> Cannabis Science is pleased to announce that the company is currently raising working capital in the European market and pursuing listings on the Frankfurt and other major European exchanges. Cannabis release

> Testosterone booster Acrux this week stormed into the black for the first time, announcing a net profit of $46.6 million after earlier in the year signing one of the biggest ever multinational licensing deals for an Australian biotech. News

> Forest Laboratories and Gedeon Richter said Monday their potential bipolar depression treatment cariprazine did non meet key goals in a midstage study. Report

> Sanofi-Aventis experimental oral medicine teriflunomide significantly reduced the relapse rate in multiple sclerosis patients, meeting the goal of a late- stage study. News

> Bionor Pharma has reported preliminary findings of its Phase II trial that served to re-immunize, or "re-vaccinate" twenty five study volunteers from its original Phase IIa study conducted in 2002/2003. Previously, at the XVIII International AIDS Conference in Vienna in July 2010, the Company reported that about half of the study volunteers retained memory to Vacc-4x seven years after their initial immunization. Bionor Pharma researchers now report that this memory can be safely reactivated following re-immunization/re-vaccination resulting in improved anti-viral responses. Bionor release

And Finally... Adelaide biotech Bionomics has presented the results of preclinical and clinical data for its anti-anxiety compound BNC210, demonstrating that the drug is more effective in treating stressed rats than the current market leader valium (Diazapem). Story

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.